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Summary 
The Norwegian Scientific Committee for Food Safety (Vitenskapskomiteen for mattrygghet, 
VKM) has at the request of the Norwegian Food Safety Authority (Mattilsynet) conducted an 
assessment of creatine in sports products (e.g. supplements). The evaluation has been 
performed by an ad hoc group, and assessed by the VKM Panel on nutrition, dietetic 
products, novel food and allergy. 
The evaluation of safety and possible risks of creatine supplementation in this opinion is 
based on previous reports, 23 original papers and 14 reviews from literature searches. 
Marketing and sales of sport products are increasing in the Nordic countries, with creatine 
supplements being one of four most common categories. In addition to be used by athletes, 
the use of creatine supplements seems to increase among general exercisers and young 
people. Creatine supplements are mainly used for their supposed effects on muscles mass and 
high intensity and short duration sport performances. Supplementation has been shown to 
result in higher concentration of creatine phosphate in the muscles, which is the limited 
substrate. 
For athletes, it is recommended a loading dose of 10-20 g/day for 4-7 days and a maintenance 
dose of 2-5 g/day for weeks or months. Some athletes continue the maintenance dose for 
several years. It is well documented that creatine supplementation has positive effects on 
muscle mass combined with strength training and performance during maximal exercise. 
There are however large individual variation in the response, and there are responders and 
non-responders.  
The new scientific literature, including long term studies, is in line with the EFSA (European 
Food Safety Authority) opinion from 2004. 
VKM Panel on nutrition, dietetic products, novel food and allergy supports the EFSA 
conclusion that supplementation of creatine in doses below 3 g/day is unlikely to pose any 
risks if the purity of the creatine compound is adequate.  
Scientific long-term studies with doses up to 5-10 g/day in adult athletes have shown no 
harmful effects, but there are no dose-response studies indicating a safe upper limit for 
creatine.  
The potential negative effects (impaired kidney function, weight gain and gastrointestinal 
disturbances) which have been published in non scientific journals and anecdotal reports have 
not found support in controlled systematic studies on healthy subjects. It has been indicated 
that individuals with impaired kidney functions should refrain from creatine supplements. 
Creatine-monohydrate is the most studied form of creatine supplements, and only creatine 
monohydrate has been included in the scientific investigations on adverse effects.  
 
Norsk sammendrag 
Vitenskapskomité for mattrygghet (VKM) har på oppdrag fra Mattilsynet gjennomført en 
vurdering av kreatin i sportsprodukter (for eksempel kosttilskudd). Vurderingen er utarbeidet 
av en ad hoc-gruppe, og godkjent i VKMs faggruppe for ernæring, dietetiske produkter, ny 
mat og allergi. 
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Denne risikovurderingen av kreatintilskudd er basert på tidligere rapporter og vurderinger 
samt 23 enkeltstudier og 14 oversiktsartikler fra litteratursøk. Den nye vitenskapelige 
litteraturen, som også inkluderer langtidsstudier, er i samsvar med EFSAs vurdering fra 2004. 
Markedsføring og salg av sportsprodukter i de nordiske landene er økende, og kreatintilskudd 
er en av de fire mest vanlige typer tilskudd blant sportsproduktene. Bruk av kreatintilskudd 
synes å øke også blant mosjonister og ungdom. 
Kreatintilskudd blir hovedsakelig benyttet på grunn av den antatte effekten på muskelmasse 
og ved idrettsaktiviteter av høy intensitet og kort varighet. Tilførsel av kreatin har vist å 
resultere i høyere konsentrasjon av kreatinfosfat i muskel – som er begrensende faktor for 
maksimal ytelse. 
For idrettsutøvere anbefales en startdose på 10-20 g/dag i 4-7 dager, og deretter en 
vedlikeholdsdose på 2-5 g/dag i uker eller måneder. Enkelte utøvere fortsetter med 
vedlikeholdsdosen i flere år.  
Det er godt dokumentert at kreatintilskudd har positiv effekt på muskelmasse og ved 
idrettsaktiviteter av høy intensitet og kort varighet. Det er imidlertid store individuelle 
variasjoner, og det er respondenter og ikke-respondenter. 
VKMs faggruppe for ernæring, dietetiske produkter, ny mat og allergi støtter EFSAs 
konklusjon om at kreatin i doser under 3 g/dag sannsynligvis ikke vil medføre noen 
helserisiko forutsatt at renhet for kreatinforbindelsen er tilfredsstillende. 
Vitenskapelige langtidsstudier med doser opp til 5-10 g/dag med voksne idrettsutøvere har 
ikke vist noen negative helseeffekter, men vi har ikke funnet dose-respons studier som 
indikerer en sikker øvre grense for kreatin. 
De potensielle negative helseeffektene (nedsatt nyrefunksjon, vektøkning og gastrointestinale 
plager) som har blitt beskrevet i ikke vitenskapelige tidsskrifter og i anekdotiske rapporter er 
ikke dokumentert i kontrollerte systematiske studier med friske personer. Det har blitt antydet 
at personer med nedsatt nyrefunksjon bør unngå kreatintilskudd. 
Kreatinmonohydrat er den mest studerte formen for kreatintilskudd, og bare 
kreatinmonohydrat inngår i studier som fokuserer på negative helseeffekter. 
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1 Background 
Sports products (e.g. supplements) are classified and regulated as foods for particular 
nutritional uses. Creatine is not included in the list of substances that may be added to foods 
for particular nutritional uses (commission regulation No 953/2009). Substances other than 
those on the list may be added to foods for particular nutritional uses on the condition that 
they are safe and suitable. 
According to a Nordic consumer survey1, the marketing and sales of sport products are 
increasing in the Nordic countries. Grouped together, various creatine supplements are one of 
the four most common categories of sports products, with creatine capsules being the most 
common creatine supplement in Norway2.  
In Denmark, only creatine monohydrate in compliance with a national specification for DK, 
126 creatine, is permitted on the market. The Danish Veterinary and Food Administration has 
also implemented regulations of permitted daily dose of this creatine compound with special 
labelling requirements. 
Previous safety opinions and assessments have been valuable background documents in this 
VKM assessment. These previous assessments are:  
 Diet and nutrition in sport from the Swedish Sport Confederation (Eva Blomstrand & 
William Apró, 2009) 
 Creatine monohydrate for use in foods for particular nutritional uses (EFSA, 2004) 
 Food and performance – Dietary guidelines for athletes (Mat og prestasjon – 
Kostholdsanbefalinger for idrettsutøvere) (Sosial- og helsedirektoratet, 2003) 
 Report of the Scientific Committee on Food on composition and specification of food 
intended to meet the expenditure of intense muscular effort, especially for sportsmen 
(SCF, 2001) 
 Assessment of the risks of creatine on the consumer and of the veracity of the claims 
relating to sports performance and the increase of muscle mass (AFSSA, 2001) 
 
2 Terms of reference 
The Norwegian Food Safety Authority has requested the following assessment of creatine in 
sports products3. 
 
1. Which adverse health effects have been reported due to intake of different forms of 
creatine (creatine compounds) (in food supplements/sports products)? 
 Can an upper safe limit for different forms of creatine (compounds) be given? 
                                               
 
1 Sport Nutrition Products. A Nordic Consumer Study; TemaNord 2009-531 
2 The Nordic Market for Sports Nutrition Products. A Market Analysis Using Norway as Case; TemaNord 2009-
530 
3 Norsk mandat i Annex 1 
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 Is new scientific evidences published, or are the conclusions in the Creatine 
monohydrate for use in foods for particular nutritional uses; EFSA opinion 
from 2004 still valid? Does VKM support the conclusions in this EFSA 
opinion? 
 Have certain groups in the population been identified that should avoid 
consumption of creatine in sports products? 
 Have special risks been identified which can be connected to consumption of 
creatine in sports products in Norway? 
 
2. Does creatine affect muscle mass? Have other beneficial effects from creatine 
supplements been identified? 
 
3 Introduction 
Creatine (N-(aminoiminomethyl)-N-methyl glycine) is a naturally occurring compound made 
in the liver, kidneys and pancreas from the essential amino acids arginine, glycine and 
methionine. In the human body approximately 95% of the total creatine pool is located in the 
skeletal muscle. Of this, approximately two-thirds exist as phosphocreatine (PCr) and one-
third as free creatine. PCr serves a major role in energy metabolism.  
The relative importance of PCr during exercise is dependent on the nature of the exercise. For 
most exercise situations, the demand for ATP is predominately provided through oxidative 
phosphorylation in the mitochondria  
When energy demand increases, PCr donates its phosphate to ADP to produce ATP, 
providing energy at high rates for a few seconds until the PCr store is emptied. Theoretically, 
an increased PCr concentration should increase the energy reserve during maximum short 
term exercise, as PCr is a limiting factor for maintenance of ATP resynthesis during such 
exercise. In spite of the high concentration of creatine in the muscles, no creatine is 
synthesised in the muscles, but mainly in the liver, and are then being transported in blood to 
the muscles. In addition to the endogenously produced creatine, creatine is obtained through 
foods, mainly meat and fish, but also from food supplements. The daily turnover of creatine is 
estimated to approximately 2 gram with about 1 gram being produced in the body and 1 gram 
coming from foods. The main breakdown of creatine and phosphocreatine to creatinine takes 
place in the muscles by splitting off H2O and phosphate, respectively. Creatinine is being 
excreted in the urine through the kidneys.  
Creatine supplements are mainly used for their supposed effects on muscle mass and high 
intensity and short duration sports performances. Creatine phosphate in the muscle is the 
limiting substrate for maximum capacity during these exercises and supplementation has been 
shown to result in a higher concentration of creatine phosphate in the muscles (Harris et al., 
1992). 
The possible ergogenic effect of creatine has led to its widespread use of supplementation in 
sport (LaBotz & Smith, 1999; Ronsen et al., 1999; Greenwood et al., 2000; Sheppard et al., 
2000; McGuine et al., 2001; McGuine et al., 2002). Ronsen et al. showed that 45% of 
Norwegian power sport athletes (boxers, weightlifters and track and field athletes) on 
National level were regular or occasional users of creatine. A later study determined the use 
of diet supplements in the total population of elite athletes in Norwegian National Teams (76 
and 92% response rate in men and women, respectively) (Sundgot-Borgen et al., 2003). It was 
found that 12% of men and 2% of female athletes used creatine, compared to 3% and 0% 
(men and women) in a randomly selected control group from the general population.  
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In addition to increased use by athletes, the use of creatine supplements seems to increase also 
among general exercisers and young people. Other population groups that might benefit from 
the claimed effects of creatine are elderly and individuals with decreased muscle mass 
(McMorris et al., 2007; Gualano et al., 2010a). 
For athletes, it is commonly recommended a loading phase dose of 10-20 g/day for 4-7 days 
and a maintenance dose of 2-5 g/day for weeks or months. This supplementation-regime can 
according to the manufacturers be repeated. Some athletes continue this maintenance dose for 
several years (Poortmans & Francaux, 2000).  
Previous reports (SCF, 2001; AFSSA, 2001; Eva Blomstrand & William Apró, 2009) 
conclude that there are positive effects of creatine supplementation in certain sports. Scientific 
studies published before and after these reports are in line with this conclusion. The focus in 
this VKM assessment will therefore be mainly on safety. 
 
4 Data sources 
Previous safety opinions and assessments that have been evaluated are listed in chapter 1 
Background. 
In addition, the following literature searches were performed in PubMed. The general creatine 
searches were limited to publications from 2004 and later, i.e., from the publication of the 
latest EFSA opinion. Furthermore, earlier dose-response studies have been evaluated because 
such studies have not been performed in the last years. 
Search 1: Creatine supplementation in title or abstract: 481 articles in total; 197 articles from 
2004 and later found. All abstract from the 197 papers published after 2004 was reviewed in 
order to look at main effects on performance and in order to identify papers dealing with 
safety aspects.  
In addition to this search, the following searches were done in order to cover other papers on 
the safety issue: 
Search 2: Creatine AND adverse OR safety OR risk OR high dose OR kidney OR renal OR 
side effects from 2004 and later: 46 (14 reviews and 32 original) articles found. 
In addition, searches for other types of creatine than creatine monohydrate were conducted: 
Search 3: Creatine pyruvate: 4 articles found. 
Search 4: Creatine citrate: 6 articles found. 
Finally, a last search was done to get all review papers on performance effects published in 
2009 and 2010: 
Search 5: Creatine supplementation in title OR abstract, review published 2009 or later: 8 
review papers found. 
All papers in search 2-4 was reviewed in full text and discussed together with the four reviews 
in search 5 dealing with performance aspects. 
 
5 Identification and characterisation of creatine 
5.1 Characteristics of creatine 
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Creatine N-(aminoiminomethyl)-N-methyl glycine is an amino acid derivative synthesised 
from arginine, glycine, and methionine mainly in the liver (approx 95%), but also in the 
kidneys, and pancreas. The synthesis rate is about 1–2 g/d (Walker, 1979).  
Creatine can also be obtained through the diet, mainly from meat and fish (Table 1). The 
average daily intake from the diet is about 1 g creatine (Walker, 1979). Normal turnover rate 
of creatine is about 2 g/day. Consequently, endogenous synthesis and intake from the diet 
covers the daily turnover (Walker, 1979). 
Creatine levels in the body will affect both the absorption in the intestines, uptake in tissues 
and clearance from the kidneys. When skeletal muscle stores become saturated, which is the 
case with repeated doses, the bioavailability of creatine decreases. Components like protein 
and carbohydrates in the food may also affect bioavailability (Bemben & Lamont, 2005; 
Buford et al., 2007). 
Creatine monohydrate is the most studied form of creatine supplements, but also creatine 
pyruvate (4 studies), creatine citrate (6 studies), and polyethylene glycosylated creatine (1 
study) have been studied. In addition, creatine in the form of Kre-Alkalyn is reported in some 
non-scientific papers (see below).   
In Denmark creatine monohydrate (N-(aminoiminomethyl)-N-methyl glycine) is the only 
form of creatine accepted for use after approval4. The reference for control of the specification 
is Guide to JECFA Specification, FAO Food and Nutrition, Paper no. 5, revision 2 from 1991. 
The Danish Veterinary and Food Administration has accepted the use of creatine 
monohydrate in a daily dose of 2-3 g/day. It is expressed specifically that the products should 
only be used by athletes during short dynamic disciplines. The Danish reference for use of 
creatine monohydrate is the EFSA opinion (EFSA, 2004). 
Another product of creatine which has been submitted for approval in Denmark is Kre-
Alkalyn. The work on the approval for this product has not been concluded.  
Some work has been performed on Kre-Alkalyn by a Bulgarian research team with 
commercial interests in this compound. No health effects have been observed with this 
compound, and they claim that the stability of Kre-Alkalyn is superior to creatine 
monohydrate. It is however important to stress that these reports have not been published in 
scientific journals. 
 
5.2 Absorption and bioavailability 
Uptake of creatine in the intestines occurs via transporters (McCall & Persky, 2007). These 
transporters have been identified in ileum and jejunum (in rodents) and both on the apical and 
basolateral membrane of enterocytes. A study of Persky et al. indicates two peaks in the 
concentration-time curve after a single dose of creatine, which may suggest more than one 
uptake mechanism (Persky et al., 2003). At the present, only limited scientific research is 
available to determine mechanisms for absorption of creatine in the human intestine.  
It is not known which form of creatine delivers the largest fraction of the administered dose, 
but in solid form creatine may be incompletely dissolved in the intestines and thus not be 
                                               
 
4 Specification for DK 126 Creatin, Fødevarestyrelsen 1. november 2004 
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absorbed. Furthermore, the bioavailability of supraphysiological doses of creatine is 
unknown.  
Harris et al. compared the relative bioavailability of 2 g creatine in different forms. Results of 
plasma peak concentration showed that solution > suspension = pills > meat. Little difference 
was found in time to peak concentration, but the shape of the concentration-time curves 
varied for the different creatine forms, suggesting differences in absorption kinetics (Harris et 
al., 2002).  
In a study of Jager et al. the bioavailability of three forms of creatine supplements (creatine 
pyruvate, creatine monohydrate and creatine citrate was tested according to the increase in 
creatine plasma values after oral intake of 4.4 g (Jager et al., 2007). Mean area under the 
curve (AUC) for plasma creatine values was higher after the creatine pyruvate intake than 
after the creatine monohydrate and creatine citrate intake (14-17% higher AUC). However, no 
significant differences between creatine forms were found for estimated velocity for 
absorption or elimination. Because creatine monohydrate already is reported to be absorbed 
close to 100% (Deldicque et al., 2008), the authors concluded that the bioavailability of these 
three forms of creatine are similar and that the small differences found in kinetics are unlikely 
to have any significant effects on the availability to increase muscle creatine levels during 
loading phases.  
The polyethylene glycosylated form of creatine was shown to have similar effects as creatine 
monohydrate on strength and high intensity exercise performance in one study, despite the 
fact that creatine in the polyethylene glycosylated form of creatine was administered in lower 
doses than in the creatine monohydrate form (1.25 or 2.5 g vs. 5 g creatine per day) (Herda et 
al., 2009). It is therefore concluded in this study that creatine in the polyethylene glycosylated 
form has comparable ergogenic effects to creatine monohydrate, and consequently the 
bioavailability of creatine should also be comparable.  
Several studies (Green et al., 1996a; Green et al., 1996b; Steenge et al., 2000) have indicated 
an enhanced absorption of creatine in the muscles when carbohydrates and/or protein are 
consumed together with creatine. Also physical activity seems to increase the uptake of 
creatine in the muscles (Harris et al., 1992; Robinson et al., 1999).  
In conclusion, the bioavailability of different creatine forms seems to be high, and there seems 
to be no major differences between creatine monohydrate and the other forms tested.  
 
5.3 Creatine distribution 
Creatine is distributed in many tissues, especially those with high energy demands, e.g., brain, 
eyes, cardiac muscle, skeletal muscle, testes and kidneys (Walker, 1979; Wyss & Schulze, 
2002). More than 95% is found in skeletal muscle. Distribution volume of creatine is close to 
that of total body water (approx 45 l). Creatine is transported in plasma in unbound form, but 
a small fraction (<10%) may be associated/bound to plasma protein. 
Creatine disposition is mainly studied in skeletal muscle. Uptake into muscle fibres is 
predominately by way of a sodium-chloride dependent creatine transporter (Persky et al., 
2003). A variety of mechanisms can regulate the transporter and thus creatine uptake rates, 
e.g., phosphorylation and glycosylation, in addition to changes in extra- and intracellular 
creatine content. Ingesting creatine with a carbohydrate source may enhance uptake, primarily 
through the effect of insulin stimulation of the receptor (Harris et al., 1992; Green et al., 
1996a). Thus, glucose is a more potent stimulant than fructose.  
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The normal concentration of total creatine in skeletal muscle is about 120 mmol/kg (dry mass) 
(Harris et al., 1992; Hultman et al., 1996), whereas the upper limit appears to be about 150–
160 mmol/kg, and in this way muscle stores of creatine will be saturated. One possible 
mechanism for this is down regulation of creatine transporter function or number, but there is 
little evidence to support this at the present. Interestingly, no saturation of creatine 
accumulation in brain has been found, but similar doses of creatine intake leads to a lower 
increase in brain creatine compared to muscle creatine (McCall & Persky, 2007). 
In humans, the Km for plasma membrane transport is in the order of 20-100 µM. Plasma 
concentration is 25-50 µM under normal conditions, which is in the range of the Km of the 
transporter. This kinetics keeps interstitial concentrations at approximately 40% of plasma 
concentrations (Persky et al., 2003). Under normal conditions, creatine kinase reaction is at 
equilibrium with about 2/3 of cytosolic creatine being in the phosphorylated form (Meyer et 
al., 1984).  
 
5.4 Removal from circulation 
In healthy individuals, creatine is cleared from the blood by both kidneys and muscles (since 
muscles irreversibly trap and use creatine). The proportion of contribution from the two 
tissues probably depends on dosage of intake and dose frequency. Creatine clearance in 
muscles may be affected by the same factors that affect the transporters, including insulin, 
IGF-1, catecholamine, exercise and intracellular creatine concentrations. Since large muscle 
mass probably corresponds to a higher number of transporters and larger storage capacity, it 
seems more correct to scale the dosing to body mass or lean body mass. Findings of creatine 
transporters in the kidneys support that creatine can be reabsorbed from preurine (Nash et al., 
1994). In unsupplemented condition, the renal clearance of creatine is 0.3-0.8 l/ h which is 
much less than the glomerular filtration rate (GFR) (approx 7 l/h) (Poortmans et al., 1997; 
Poortmans et al., 2005). Clearance increases to 9-22 l/h under supplemented conditions. This 
is higher than the glomerular filtration rate and implies secretion of creatine from the blood 
into renal tubules.  
 
6 Evaluation of documentation - effect on performance 
The evaluation of the effects on performance from creatine supplementation is based on the 
previous reports (SCF, 2001; Eva Blomstrand & William Apró, 2009) and the literature 
search in PubMed limited to reviews from 2009/2010 (after the Swedish report), as described 
in chapter 4 (Data sources). 
 
6.1 Summary from the Swedish report “Diet and nutrition within sports” 
regarding creatine supplements for athletes – effect on performance 
Eva Blomstrand, Associate Professor in physiology and lecturer at The Swedish School of 
Sport and Health Sciences was given the task by the Swedish Sports Confederation to make a 
survey of the published scientific studies concerning diet and athletics. The report Diet and 
nutrition in sport was published in December 2009 (Eva Blomstrand & William Apró, 2009). 
In this report a chapter about the use of creatine monohydrate supplement is included. This 
section is a résumé of the creatine chapter.  
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According to the Swedish report, supplementation with creatine has been shown to result in 
higher concentrations of creatine phosphate in the muscles and an improvement of explosive 
performances of short durations, especially with repeated maximum performances. The 
mechanism behind the enhanced exercise capacity is based on the fact that creatine phosphate 
is the limiting substrate for maximum capacity. Normally the storage of creatine is sufficient 
for 5-8 seconds maximum performance (Newsholme & Leech, 1983), but with increased 
levels in the muscles the performance can be maintained for a longer period. In the majority 
of the studies showing enhanced performance, the exercise is of high intensity and short 
duration. 
The Swedish report further states that creatine supplementation has also shown enhanced 
effects in relation to strength performances. The scientific literature supports that 
supplementation with creatine in combination with strength training over longer periods 
results in increased maximum strength, increased ability for high intensity performance and 
also increased muscle mass compared with strength training without creatine 
supplementation. 
According to the Swedish report, creatine supplementation generally results in increased 
levels of creatine in the muscles, but with large individual variation (Harris et al., 1992; 
Greenhaff et al., 1994). The reason for the large variation in response is not fully understood, 
but the initial level of creatine in the muscles before supplementation seems to be of 
importance (Burke et al., 2003). The enhancement of the performance also shows large 
differences between individuals, possibly explained by variations in the uptake of creatine 
(Harris et al., 1992).  
 
6.2 Summary from report of the Scientific Committee on Food on 
composition and specification of food intended to meet the expenditure 
of intense muscular effort, especially for sportsmen – effect on 
performance 
In 2001 the Scientific Committee on Food (SCF) reviewed the scientific literature in the area 
of sport nutrition as well as a number of consensus reports prepared by various sport 
organisations (SCF, 2001). SCF concluded that the concept of a well-balanced diet is the 
basic requirement for athletes. Nevertheless, taking into consideration the aspects of intense 
muscular exercise such as intensity, duration, frequency, time and convenience, it was 
suggested that individuals can benefit from particular foods or food ingredients beyond the 
recommendations for the general population. In this aspect creatine has been mentioned 
separately. 
SCF states that creatine ingestion increases the total creatine content in human muscles by 
approximately 15-20% (mean value). Similar to the Swedish report, they also stress that the 
increase is rather variable between subjects, ranging from zero to 40%, showing that there are 
responders and non-responders. 
 
6.3 Reviews and other studies 
In 2009/2010 a total of nine new reviews on creatine supplementation were published. 
However, eight of these reviews have a clinical approach and do therefore not discuss effects 
on sports performance. These reviews do therefore not add to the information summarised in 
the Swedish report. The last review focuses on the possible effects of creatine 
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supplementation on heat tolerance and hydration status (Lopez et al., 2009). The conclusion 
in this review is that creatine supplementation does not hinder the body's ability to dissipate 
heat or negatively affect the athlete's body fluid balance.  
 
6.4 Discussion effect on performance 
It is well documented that creatine supplementation can increase high intensity short duration 
exercise performance due to the elevated levels of creatine phosphate found after 
supplementation. It is also well documented that creatine supplementation during strength 
training can enhance the increase in muscle strength and muscle mass. However, it is 
important to note the large individual variations in the response. Consequently, there are both 
responders and non-responders to the normal creatine supplementation regimens. In some 
studies, it is estimated that 20-30% of a normal population will be non-responders. 
Furthermore, already high levels of muscle creatine phosphate may be the main explanation 
for why some people do not increase creatine levels in response to creatine supplementation. 
Most studies on the effect of creatine supplementation on sports performance include 
intervention periods lasting up till 16 weeks. The long-term effect of creatine supplementation 
on exercise performance is therefore less studied. Furthermore, several athletes use creatine 
repeatedly with some weeks or months between each supplementation period. So far the 
effect of this cycling on and off creatine supplementation has not been extensively studied.   
 
6.5 Conclusion evaluation of documentation for effect on performance 
Supplementation with creatine has been shown to result in a higher concentration of creatine 
phosphate in the muscles. In most studies, a loading phase of 20 g/day for 5-7 days is 
followed by a maintenance period (weeks-months) where the intake is reduced to 2-5 g/day. 
The majority of studies have shown that creatine supplementation enhances performance in 
high intensity and short duration sport activities, especially if high intensity exercise is 
repeated with short recovery time (< 1 min) between the intense exercise bouts. 
Enhanced effect has also been shown in relation to strength performance. When combined 
with strength training, creatine supplementation may also increase muscle mass. 
It is important to underline that there are individual variations, and that there are responders 
and non-responders. 
 
7 Evaluation of safety 
The evaluation of safety and possible risks related to creatine supplementation is based on the 
previous reports (SCF, 2001; AFSSA, 2001; EFSA, 2004; Eva Blomstrand & William Apró, 
2009), 23 original papers, and 14 reviews from the literature searches in PubMed, described 
in chapter 4 (Data sources). 
 
7.1 Summary from the Swedish report “Diet and nutrition within sports” 
regarding creatine supplements for athletes – safety 
This section is a résumé of the safety aspect in the creatine chapter in the Swedish report. 
According to the Swedish report (2009) the use of creatine has been widely discussed after 
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being introduced on the market, and has been claimed to be both dangerous and unnecessary 
(Buford et al., 2007). The potential negative effects claimed in non scientific journals, have 
not found support in systematic studies in healthy subjects (Terjung et al., 2000; Bemben & 
Lamont, 2005; Buford et al., 2007).  
Concerns have particularly been related to a proposed negative effect on renal function, as the 
creatine ingested is removed by the kidneys and excreted through the urine. The main 
reference in this regard is a case study based on one person with an already existing kidney 
problem (Pritchard & Kalra, 1998). Other scientific studies have not found any negative 
effects of creatine supplementation on kidney function or other health parameters. (Poortmans 
& Francaux, 1999; Greenwood et al., 2003; Poortmans et al., 2005; Pline & Smith, 2005; 
Gualano et al., 2008). 
In the Swedish report it is underlined that it is important to be aware of the fact that long-term 
studies (more that 5 years) on creatine’s possible health effects are missing.  
The report further claims that individuals with reduced kidney function should refrain from 
creatine supplementation.  
In this report no safe upper level for intake of creatine is given. 
 
7.2 Summary of the EFSA opinion 2004 ”Creatine monohydrate for use in 
foods for particular nutritional uses” - safety 
The SCF from 2001 expressed that the evidence is insufficient to provide reassurance about 
safety of creatine supplementation involving high loading doses. This report also pointed out 
that little information exists on long term safety of creatine and that adequate quality control 
and specifications for food grade materials should be developed.  
In the EFSA opinion from 2004 only creatine monohydrate with high purity (minimum 
99.95%) is considered (EFSA, 2004).  
This EFSA panel underline, however, that little information exits both on the short-term and 
long-term safety of creatine and adequate quality control of the commercially marked creatine 
is lacking. 
They also stress that even if trials have studied the effects of creatine, large scale well-
controlled studies are lacking, and that available results observed in highly trained athletes 
cannot necessary be extrapolated to the general public. 
The EFSA opinion says that although no important adverse effects have been reported in the 
efficacy trials, such evidence is insufficient to provide reassurance about the safety of creatine 
supplementation involving high loading doses. Among others, there are doubts about safety in 
relation to kidney function. 
The EFSA panel endorses the previous opinion of the SCF that high loading doses of creatine 
should be avoided. The EFSA Panel considers that consumption of doses up to 3 g/day is 
unlikely to pose any risk. 
The petitioner reports that the acute toxicity of creatine monohydrate is low and not 
mutagenic in the Ames test. This has been tested in a 28-day rat study with doses up to 2 g/kg 
bw/day. 
A human study indicates that creatine monohydrate supplementation for up to 21 months does 
not appear to adversely affect markers of health status in athletes (Kreider et al., 2003).  
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In this study the subjects were given 15.75 g/day of creatine monohydrate for 5 days and an 
average of 5 g/day thereafter in 5-10 g/day doses. 
No specific assessment of exposure of creatine monohydrate was considered necessary 
provided the intake of creatine is within the amounts judged unlikely to pose any risk (2-3 
g/day). 
 
7.3 Summary from “Report of the Scientific Committee on Food on 
composition and specification of food intended to meet the expenditure 
of intense muscular effort, especially for sportsmen” 2001 - safety 
In spite of numerous anecdotal reports of creatine supplementation causing gastrointestinal, 
cardiovascular and muscular problems, no scientific evidence support these reports. 
Even if creatine supplementation increases urinary creatine and creatine excretion, the SCF 
report claims that there is no a priori reason to expect that acute and long-term creatine 
ingestion impairs kidney function in healthy individuals. 
The SCF could, however, not conclude that creatine supplementation is free from health risks 
as documentation was lacking or incomplete. 
 
7.4 Assessment of the AFSSA-report “Risks of creatine on the consumer 
and of the veracity of the claims relating to sports performance and the 
increase of muscle mass” 2001 - safety  
A 2001 report by the Food Safety Agency of France (AFSSA) (http://www.afssa.fr/) raised 
questions about creatine supplements possibly putting users at risk for cancer, particularly if 
supplements are taken for long periods of time (AFSSA, 2001). However, the European 
Commission and the Council for Responsible Nutrition in the United States both determined 
that AFSSA’s claims were unsubstantiated and not based on any scientific evidence of 
connection between creatine and cancer. All three organisations do agree,that risks of long-
term use of creatine are not known. 
 
7.5 Reviews and other studies-safety 
A total of 23 original papers and 14 reviews/meta analyses discussing the safety of creatine 
supplementation are published after 2004, according to PubMed. The use of creatine 
evaluated in most studies includes a loading phase of 20 g/day for 4-7 days followed by a 
maintenance phase of 2-5 g/day. The total supplementation period varies from 1 week to  
6 months in most studies.  
The findings in the 23 original papers are summarised in annex 2. The investigated possible 
adverse effects are mostly related to renal function, liver function, gastrointestinal problems 
and risk factors for cardiovascular disease (Bizzarini & De, 2004; Bemben & Lamont, 2005; 
Francaux & Poortmans, 2006; Persky & Rawson, 2007). Further, two reviews focus on 
possible side effects related to acclimatization to the heat (Dalbo et al., 2008; Lopez et al., 
2009). The suggested possible adverse effect of taking creatine supplements in a warm 
climate is not supported in these reviews. 
One review is focusing on the use of creatine in paediatrics (Evangeliou et al., 2009). In this 
review positive effects of creatine supplementation are listed for a number of diseases and no 
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adverse effects are mentioned. The use of creatine supplementation in healthy children is, 
however, not discussed. 
In the short term studies (5-14 days) high doses of creatine were administered throughout the 
intervention period (~ 20 g/day, (Santos et al., 2004; Poortmans et al., 2005; Ahmun et al., 
2005; Hile et al., 2006; Armentano et al., 2007; Gotshalk et al., 2008)). Except for increased 
serum levels of creatine and/or creatinine, no adverse effects were reported in these studies. In 
line with the findings in the acute studies, no adverse effects were reported in the studies on 
healthy men and women taking creatine supplement for 4-12 weeks (Cancela et al., 2008; 
Gualano et al., 2008; Ostojic & Ahmetovic, 2008). The longest well controlled study lasted 
for 310 days and was performed on patients with the neurodegenerative disease amyotrophic 
lateral sclerosis (Groeneveld et al., 2005).The patients were administered either 10 g creatine 
per day or a placebo. During the intervention period selected adverse effects were measured 
by questionnaire and in blood and urine samples. No differences between groups were 
observed for nausea, gastrointestinal discomfort, plasma urea levels or micro-albuminuria. 
However, oedematous limbs were seen more often in subjects using creatine, probably due to 
water retention.  
In one study, professional basketball players consuming 5 g creatine per day were followed 
through three competition seasons (total of 3 years) (Schroder et al., 2005).Within each 
season, a total of 5 blood samples were drawn and analysed, and between seasons there was a 
2 month off-season without creatine supplementation. Amongst the 16 health-variables 
measured, only the levels of creatinine and creatine kinase increased to values higher than the 
clinical reference values. Increased level of creatine kinase is normally seen after high 
intensity exercise and is therefore probably not related to the supplementation. Furthermore, 
increased plasma creatinine level is often reported with creatine supplementation and this 
elevation is not related to impaired renal function, but simply reflects the increased 
conversion of creatine to creatinine with increased creatine intake. 
The ratio of dihydrotestosterone/testosterone was found to be increased after creatine 
supplementation in one study (Van Der Merwe et al., 2009). It is however not possible to 
conclude whether this change in dihydrotestosterone/testosterone ratio is an adverse effect of 
creatine supplementation and the authors speculate whether this change in testosterone 
metabolism could be one cause behind the observed positive effects on muscle mass. 
The longest reported follow-up on possible adverse effects of creatine supplementation is 5 
years (Poortmans & Francaux, 1999). In this study athletes reporting self administration of 
creatine supplements were compared with matched controls for several markers of renal 
function. The creatine users had taken creatine for 10 months up to 5 years and the daily doses 
ranged from 1 g/day up to 80 g/day. The main result in this study was that glomerular 
filtration rate, tubular reabsorption, and glomerular membrane permeability were normal in 
both groups. Consequently, the authors concluded that neither short-term, medium-term, nor 
long-term oral creatine supplements induce detrimental effects on kidneys in healthy 
individuals. 
The effect of creatine supplementation in different patient populations has been studied for 
various durations ranging from 4 days to 2 years (Braegger et al., 2003; Taes et al., 2004; 
Roitman et al., 2007; Taes et al., 2008; Bender et al., 2008; Jahangir et al., 2009; Gualano et 
al., 2010b). In the study of Jahangir it was reported that creatine supplementation in patients 
with coronary artery disease (21 g/day for four days) significantly increased the concentration 
of plasma total homocysteine, which could be a risk factor for cardiovascular disease. The 
clinical relevance of increased homocystein is still under discussion. Except for this effect and 
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one patient reporting muscle pain and increased serum levels of creatinine in two other 
studies, no adverse effect of the creatine supplementation was reported. 
In addition to the reported placebo-controlled trials reported, two case-reports were also 
included in this evaluation. In one case, a unilateral nephrectomised patient followed a normal 
creatine supplementation regimen (20 g/day for 5 days followed by 5 g/day for 30 days) 
without any signs of adverse effects on kidney function (Gualano et al., 2010b). In the other 
case report, a male bodybuilder who experienced acute renal failure was characterised 
(Thorsteinsdottir et al., 2006). The bodybuilder reported a use of 15 g creatine per day for the 
last 6 months. In addition, several other supplements were used in this period and it was not 
possible to establish a cause-effect relation between the creatine use and the acute renal 
failure. 
In general, no strong scientific evidence for adverse effects is found, but some studies remark 
that the issue of long-term use (several years) has not been properly addressed. In addition, 
possible risks for patients with renal disorders are mentioned in one of the reviews (Francaux 
& Poortmans, 2006).  
No literature comparing safety and purity in different creatine compounds were found.  
 
7.6 Special groups 
No studies have been found on possible adverse effects of creatine supplementation on 
healthy children or adolescents. The effect of creatine supplementation in young patient 
groups has been discussed in a review paper (Evangeliou et al., 2009), but possible adverse 
effects were not in focus. Consequently, it is not possible to conclude on eventual adverse 
effects of creatine supplementation in children. 
 
7.7 Summary and conclusion adverse events related to creatine 
The EFSA opinion concludes that the safety and bioavailability of creatine and creatine 
monohydrate in foods for particular nutritional uses, is not a matter of concern provided that 
there is adequate control of the purity of the source of creatine with respect to dicyandiamide 
and dihydro-1,3,5-triazine derivatives (EFSA, 2004).  
The EFSA Panel endorses the previous opinion of the SCF that high loading doses of creatine 
should be avoided. Provided high purity creatine monohydrate is used in foods for particular 
nutritional uses, the EFSA Panel agrees with the opinion of the SCF that the consumption of 
doses of up to 3g/day of supplemental creatine, similar to the daily turnover rate of creatine, is 
unlikely to pose any health risk. 
It is also stated in the EFSA opinion that although many efficacy trials have studied the 
effects of creatine, large-scale, well-controlled studies of potential adverse effects are lacking. 
They also underline that available results observed in highly trained athletes cannot 
necessarily be extrapolated to the general public. 
The Swedish report underlines that individuals with reduced kidney function should refrain 
from supplementation of creatine (Eva Blomstrand & William Apró, 2009).  
Only creatine monohydrate has been included in the scientific investigations on adverse 
effects. Among the reviews found in the literature no adverse health effects have been 
reported. 
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VKM Panel on nutrition, dietetic products, novel food and allergy supports the EFSA 
conclusion that supplementation with creatine up to 3 g/day (close to turnover rate) is unlikely 
to pose any health risks. Scientific long-term studies with doses up to 5-10 g/day in adult 
athletes have shown no harmful effects.  
In most studies, athletes or physically active subjects are investigated. Consequently, these 
results do not give reassurance about potential long-term effects of high doses of creatine in 
people who are not highly trained or belong to other population subgroups. However, the 
longest controlled trial was performed in a patient group, and a growing number of studies in 
patients and elderly support the findings from the studies in athletes.  
 
8 Exposure 
8.1 Duration of use of creatine supplements 
Most studies investigating performance or health related aspects of creatine supplementation 
have been of 4-12 weeks duration. Supplementation often starts with a loading phase of 20 
g/day for 4-7 days. This loading phase is followed by a maintenance phase of 2-5 g/day. In 
addition to these well controlled short term studies, there are some long-term studies, but most 
of these are less controlled. 
The longest well controlled study lasted for 310 days and was performed on patients with the 
neurodegenerative disease amyotrophic lateral sclerosis (Groeneveld et al., 2005).The patients 
were administered either 10 g creatine per day or a placebo. 
In one study, professional basketball players consuming 5 g creatine per day were followed 
through three competition seasons (total of 3 years) (Schroder et al., 2005) 
The longest reported follow-up on possible adverse effects of creatine supplementation is 5 
years (Poortmans & Francaux, 1999). 
 
8.2 Content of creatine in some foods 
Creatine is endogenously produced mainly in the liver. The synthesis rate is about 1–2 g/day 
(Walker, 1979). Creatine can also be obtained through the diet, mainly from meat and fish 
(Table 1). The average daily intake from the diet is about 1 g creatine, whereas it may be less 
for vegetarians. Normal turnover rate of creatine is about 2 g/day. Consequently endogenous 
synthesis and intake from the diet equals the daily turnover.  
Table 1 (source: http://www.creapure.com/index.php?id=47): Creatine content of different 
foods (unprocessed) 
Food   Creatine content g/kg 
Fish Herring 6.5-10 
  Salmon 4.5 
  Tuna 4 
  Cod 3 
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Food   Creatine content g/kg 
  Plaice 2 
Meat Pork 5 
  Beef 4.5 
Other Breastmilk 0.1 
  Vegetables Trace Amounts 
  Fruit Trace Amounts 
   
 
9 Data gaps 
The risks related to long-term use and repeated doses of creatine are not known at this time. 
Few studies have investigated the safety of creatine in less trained adults and in children or 
adolescents. The risks related to creatine supplementation in individuals with reduced kidney 
function or renal diseases have not been clarified. It is likely that some (athletes) use creatine 
in combination with anabolic steroids. The impact of this combination has not been studied. 
More studies is required to confirm whether short term or long-term creatine supplementation 
in healthy individuals may increase the concentration of plasma total homocysteine. 
It is also necessary with more studies concerning the increased ratio of dihydrotestosterone 
/testosterone after creatine supplementation and the mechanisms underlying this change. 
No literature comparing safety and purity in different creatine compounds were found.  
 
10 Answer to the terms of reference 
The Norwegian Food Safety Authority has requested an assessment of creatine in sports 
products. 
 
1. Which adverse health effects have been reported due to intake of different forms of 
creatine (creatine compounds) (in food supplements/sports products)? 
 
No adverse effects from intake of creatine in doses below 3 g/day have been reported 
in well controlled systematic studies. The potential negative effects which have been 
published in non scientific journals and anecdotal reports, have not found support in 
systematic studies on healthy subjects. These negative effects include impaired kidney 
function, weight gain and gastrointestinal disturbances. All studies investigating 
adverse effects have used creatine monohydrate. Other creatine compounds have not 
been investigated for adverse effects.  
 
 Can an upper safe limit for different forms of creatine (compounds) be given? 
 
There are no dose-response studies indicating a scientifically or toxicologically 
based upper safe limit for creatine. As mentioned above, only creatine 
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monohydrate has been included in scientific literature investigating adverse 
effects. VKM Panel on nutrition, dietetic products, novel food and allergy 
supports the EFSA conclusion that supplementation with creatine up to 3 g/day 
is unlikely to pose any risks if the purity of the creatine compound is adequate.  
 
 Is new scientific evidence published, or are the conclusions in the Creatine 
monohydrate for use in foods for particular nutritional uses; EFSA opinion 
from 2004 still valid? Does VKM support the conclusions in this EFSA 
opinion? 
 
New scientific literature is in line with the EFSA opinion and supported by 
new long-term studies. VKM Panel on nutrition, dietetic products, novel food 
and allergy supports the EFSA conclusion that supplementation with creatine 
up to 3 g/day is unlikely to pose any risks if the purity of the creatine 
compound is adequate. It should also be mentioned that scientific long-term 
studies with doses up to 5-10 g/day in adult athletes have shown no harmful 
effects. 
 
 Have certain groups in the population been identified that should avoid 
consumption of creatine in sports products? 
 
It has been indicated that individuals with impaired kidney function should 
refrain from creatine supplements. 
 
 Have special risks been identified which could be connected to consumption of 
creatine in sports products in Norway? 
 
No special risks have been identified which could be connected to 
consumption of creatine supplements in Norway 
 
2. Does creatine affect muscle mass? Have other beneficial effects from creatine been 
identified? 
 
Supplementation with creatine has been shown to result in a higher 
concentration of creatine phosphate in the muscles. The majority of studies 
have shown an enhanced performance in high intensity and short duration sport 
activities from creatine supplementation. 
 
Enhanced effect has also been shown in relation to strength performance. 
Combined with strength training, creatine supplementation has also been 
shown to increase muscle mass. 
 
It is important to underline that there are individual variations, and that there 
are responders and non-responders. 
 
Other beneficial effects have been reported in some special patient groups. 
These findings range from improved muscle function in muscle diseases, 
improved well-being in cystic fibrosis patients and better glycemic control in 
type 2 diabetes patients when combined with resistance training. The strongest 
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evidence so far is the beneficial effects of creatine supplementation in 
neurodegenerative and muscular diseases. 
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Annex 1 
Mattilsynet ber VKM om en vurdering om bruk av kreatin. 
1. Hvilke negative helsemessige effekter kan foreligge ved inntak av ulike former for 
kreatin i næringsmidler? 
 Kan det settes en øvre trygg grense for de ulike formene for kreatin? 
 Mattilsynet ber om at faggruppen i denne sammenheng vurderer EFSAs 
rapport om kreatinmonohydrat publisert i 2004 (vedlegg 2), - har det skjedd 
endringer i kunnskapsstatus siden vurderingen ble foretatt eller kan 
konklusjonene i rapporten støttes? 
 Er det spesielle grupper i befolkningen som ikke bør spise produkter med 
kreatin? 
 Kan det foreligge spesielle farer knyttet til inntak av kreatin i Norge? 
 
2. Har kreatin effekt på muskelmasse? Har kreatin eventuelle andre positive effekter? 
 
Annex 2 
Table of 23 studies discussing safety of creatine supplementation published after 2004 
Study Study design Objective Subjects (n), 
age years 
Dose (g/d) and 
duration 
Primary 
outcome; 
measures, 
analysis 
GI symptoms Renal/ renal 
biomarkers 
Other AE 
Gualano et al., 
Am J Kidney Dis, 
2010 
Case-report  n=1, age=20, 
Unilateral 
nephrectomy, 
mildly 
decreased 
GFR, without 
kidney damage 
20 g/d for 5 
days, 5 g/d for 
30 days 
Renal function; 
Cr-EDTA 
clearance, 
proteinuria, 
albuminuria, 
serum urea, 
GFR 
Not measured No change  
Armentano et al., 
Mil Med, 2007 
Double-blind 
randomised 
placebo-
controlled 
clinical trial 
Performance 
and safety       
35 healthy men 
and women, 
age=22-36 
20 g/d for 7 
days 
Performance 
and safety; 
Push-ups, 
serum 
creatinine, 
blood pressure 
and renal 
function 
Not measured Increased 
serum 
creatinine  
No 
Cancela et al., 
Br J Sports Med, 
2008   
Double-blind 
randomised 
placebo-
controlled trial 
Safety 14 healthy    
soccer players 
15 g/d for 7 
days 3 g/d 49 
days 
Renal and 
hepatic function 
markers 
Not measured No change  
Ferreira et al., 
Med Sci Sports 
Exerc, 2005 
4 groups:    1) 
Cr, 2) Cr + 
exerc, 3) Exerc, 
4) Control 
Safety and 
body 
composition 
Rats 2 g/kg food for 
10 weeks 
Renal function 
and body 
composition; 
GFR and renal 
plasma flow 
 Inulin and 
paraaminohipp
urate clearance 
reduced 
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Study Study design Objective Subjects (n), 
age years 
Dose (g/d) and 
duration 
Primary 
outcome; 
measures, 
analysis 
GI symptoms Renal/ renal 
biomarkers 
Other AE 
Gotshalk et al., 
Eur J Appl 
Physiol, 2008 
Double-blind 
randomised 
placebo-
controlled trial 
Performance   30 healthy 
women, 
age=58-71 
0.3 g/kg/day for 
7 days 
 No AE 
observed 
  
Poortmans et al., 
Med Sci Sports 
Exerc, 2005 
Prospective 
cohort 
Safety 20 young 
healthy men 
21 g/d for 14 
days 
Renal function; 
Plasma and 
urine levels of 
defined 
compounds 
Not measured Increased 
serum and 
urine creatine, 
no change in 
creatinine or 
urinary albumin 
 
Taes et al.,  
Kidney Int, 2004 
Double-blind 
randomised 
placebo-
controlled trial 
Improved 
homocysteine 
levels in 
hemodialysis 
patients 
45 
hemodialysis 
patients 
2 g/d for 4 
weeks 
Homocysteine 
levels; Plasma 
homocysteine 
levels (tHcy) 
Not measured No change  
Gualano et al., 
Eur J Appl 
Physiol, 2008 
Double-blind 
randomised 
placebo-
controlled trial 
Safety (renal 
function) 
18 healthy 
men, age=18-
35 
10 g/d for 3 
months 
Renal function; 
Serum 
creatinine, 
urinary sodium 
and potassium 
and cystatin C 
(GFR) 
Not measured Decreased 
cystatin C in 
both groups 
(increased 
GFR because 
of training?) 
 
Taes et al., 
Nephrol Dial 
Transpl, 2008 
Double-blind 
randomised 
placebo-
controlled trial 
Safety 20 male 
hemodialysis 
patients 
2 g/d for 4 
weeks 
Plasma 
guanodine 
compounds 
Not measured   
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Study Study design Objective Subjects (n), 
age years 
Dose (g/d) and 
duration 
Primary 
outcome; 
measures, 
analysis 
GI symptoms Renal/ renal 
biomarkers 
Other AE 
Thorsteinsdottir 
et al., J Ren 
Nutr, 2006 
Case-report Renal failure 1 male with 
acute renal 
failure, 24 
years 
15 g/week for 6 
months 
Renal failure    
Bender et al., 
Nutr Research, 
2008 
Double-blind 
randomised 
placebo-
controlled trial 
Safety, 
particularly 
kidney function 
60 men and 
women with 
early Parkinson 
disease, 
age=60±10 
20 g/d for 6 
days, 2 g/d for 
6 months, 4 g/d 
for 1.5 yrs  
Side effects; 
Questionnaires 
and a broad 
range of blood 
and urine tests 
Significant 
increase in GI 
complaints 
after 2 yrs 
therapy 
α(1)- and ß(2)-
microglobulin, 
cystatin C, 
creatinine, total 
protein content, 
albumin, 
erythrocytes in 
the urine 
None 
Braegger et al., J 
Cystic Fibrosis, 
2003 
Open-label pilot 
study 
Effect on 
muscle 
strength, lung 
function and 
CF 
transmembrane 
conductance 
regulator 
(CFTR) 
channel activity 
18 men and 
women with 
cystic fibrosis, 
age=8-18  
12 g/d for one 
week, 6 g/d for 
11 weeks (also 
tested after 12-
24 weeks post-
treatment) 
CFTR-related 
pathological 
symptoms, 
muscle 
strength, lung 
function, 
general well-
being; 
Questionnaires 
and Isometric 
muscle 
strength, lung 
function, blood 
samples 
  One patient 
with transient 
muscle pain.  
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Study Study design Objective Subjects (n), 
age years 
Dose (g/d) and 
duration 
Primary 
outcome; 
measures, 
analysis 
GI symptoms Renal/ renal 
biomarkers 
Other AE 
Groeneveld et 
al., Nutrition, 
2004 
Double-blind 
randomised 
placebo-
controlled trial 
Disease 
progression, 
survival 
175 subjects 
with 
amyotrophic 
lateral 
sclerosis, 
age=58±11 
10 g/d (5gx2) 
for 310 days 
Adverse events 
and renal 
function; 
Questionnaires 
and blood and 
urine samples 
NS, but severe 
diarrhoea in 2 
and severe 
nausea in 1 
subject made 
them stop 
intake 
Urinary 
creatine and 
albumin, 
plasma urea 
Oedematous 
limbs higher in 
CR at 2 
months, not 
other time 
points 
Jahangir et al., 
Vasc Med, 2009  
Double-blind 
randomised 
placebo-
controlled trial 
Effect of 
creatine and 
arginine on 
vascular 
function and 
homocysteine 
level 
26-29 per 
group, CAD-
patients,  
age creatine 
group: 60±11, 
placebo: 58±12 
21 g/day (7gx3) 
for 4 days 
Cr increased 
homocysteine 
content (not 
attributed to 
worsened renal 
function); 
Brachial artery 
flow-mediated 
dilation, plasma 
guanidinoaceta
te 
NA Increase in 
cystatin C w 
reduction in 
GFR with 
combination of 
Arg and Cr 
None 
Roitman et al., 
Bipolar Disord, 
2007 
Open, clinical 
add-on trial 
Effect on 
depression 
 
10 patients (8 
unipolar and 2 
bipolar), 
age=49±10 
3 g/d for one 
week, 5 g/d for 
3 weeks 
Depression, 
anxiety; 
Depression and 
anxiety scales, 
clinical global 
impression 
scores 
None NA None 
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Study Study design Objective Subjects (n), 
age years 
Dose (g/d) and 
duration 
Primary 
outcome; 
measures, 
analysis 
GI symptoms Renal/ renal 
biomarkers 
Other AE 
Vorgerd et al. 
Acta Myol, 2007 
 Effect on 
muscle 
symptoms and 
performance in 
McArdle's 
patients  
Patients with 
McArdle 
disease 
 Clinical scores; 
Muscle 
symptomatic 
and 
performance 
NA NA NA 
Ahmun et al., J 
Strength Cond 
Res, 2005 
 Performance Healthy rugby-
players 
20 g/d for 5 
days, 28 days 
wash-out 
Repeated 
Wingate test, 
repeated sprint 
test 
Not measured Not measured NA 
Hile et al., J Athl 
Train, 2006 
 Effect on 
compartment 
pressure 
11 healthy well-
trained men, 
age=22±2 
21.6 g/d for 7 
days 
Compartment 
pressure; 
Pressure and 
pain 
Not measured Not measured Transient 
increased 
compartment 
pressure 
Ostojic et al., 
Res Sports Med, 
2008 
 Dose-response 
in relation to 
GI-distress 
59 healthy top 
level soccer 
players 
2x5 g/d or 1x10 
g/d for 28 days 
Perceived side 
effects on GI 
system; 
Questionnaire 
Episodes of 
diarrhoea: 
placebo: 35%; 
C5: 28%; C10: 
55%  (P<0.05 
vs other 
groups) 
Not measured Not reported 
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Study Study design Objective Subjects (n), 
age years 
Dose (g/d) and 
duration 
Primary 
outcome; 
measures, 
analysis 
GI symptoms Renal/ renal 
biomarkers 
Other AE 
Santos et al., 
Life Sci, 2004 
 Effect on 
inflammation 
and muscle 
soreness  after 
30 km running 
Healthy 
marathon 
runners 
20 g/d (4x5 g) 
for 5 days 
Inflammation, 
muscle 
damage, 
muscle 
soreness; 
Creatine 
kinase, LDH, 
PGE2, TNF-
alpha in blood 
Diarrhoea Not measured  
Schroder et al., 
Eur J Nutr, 2005 
 Risk 
assessment, 
long-term 
creatine 
supplementatio
n in athletes 
18 healthy 
professional 
basket players, 
age=24±4 
5 g/d, 10 
months/year for 
3 years 
Blood levels of 
16 clinical 
markers; 
Minerals, lipids, 
serum 
enzymes, 
creatinine, 
urea, uric acid 
  Creatinine and 
creatine kinase 
above 
reference 
values 
van der Merwe 
et al., Clin J 
Sport Med, 2009 
 Effect on 
dihydrotestoste
rone to 
testosterone 
ratio 
20 healthy 
rugby players, 
age=18-19 
25 g/d for 7 
days, 5 g/d for 
14 days 
Dihydrotestoste
rone 
(DHT)/testoster
one ratio; 
Concentrations 
in blood of 
dihydrotestoste
rone and 
testosterone 
Not measured Not measured  
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Study Study design Objective Subjects (n), 
age years 
Dose (g/d) and 
duration 
Primary 
outcome; 
measures, 
analysis 
GI symptoms Renal/ renal 
biomarkers 
Other AE 
Gualano et al., 
Eur J Appl 
Physiol, 2010 
 Safety and 
renal function 
25 patients with 
type 2 
diabetes, 
age=45-70 
5 g/d for 12 
weeks 
Kidney 
function; 
Cr-EDTA 
clearance, 
proteinuria, 
albuminuria, 
serum urea, 
GFR 
Not measured No change  
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